Gland Pharma Ltd reports Q2 FY27 revenue of ₹1,833.6 crore, up 23% YoY, and PAT of ₹290.8 crore, up 58%
- Consolidated EBITDA operating margin was 26%, versus 21% a year earlier and 27% in Q1 FY27; revenue rose 2% sequentially while PAT fell 8%.
- No exceptional item was recorded in Q2 FY27; FY26 included a ₹24.35 crore labour-code-related provision.
- Board approved unaudited standalone and consolidated results on November 6; auditors issued unmodified limited-review conclusions.
